MediGene AG · LS:A40ESG
MediGene — 9M 2019 Earnings Presentation
12 slides from MediGene's earnings presentation, Nov 13, 2019
Slide 1: Living Immunotherapies – 9-Months 2019 Earnings Call
Living Immunotherapies 9-Months 2019 Earnings Call 13 November 2019 Prof. Dolores J. Schendel, CEO/CSO Axel Malkomes, CFO/CBO Dr. Kai Pinkernell, CMO/CDO
Slide 2: "Safe Harbor" Statement
"Safe Harbor" Statement All of the information herein has been prepared by the Company solely for use in this presentation. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no relian
Slide 3: Medigene – Key information
Medigene – Key information Company Listing Based in Martinsried, near Munich, Frankfurt Stock Exchange (MDG1) Germany 24.6 m shares outstanding ~ 140 employees ~ €150 m market cap** €60.5 m cash* Technology innovation Near-term catalysts TCR discovery engine DC vaccine Phase I/II trial in AML patien
Slide 4: Medigene's growing immunotherapy pipeline
Medigene‘s growing immunotherapy pipeline Project Indication (Target) Preclinical Phase I Phase II Partner MDG1011 AML, MDS, MM (PRAME) MDG1021 Post-HSCT relapse (HA-1) TCR-T MDG10XX Solid tumors bluebird bio Undisclosed (MAGE-A4) Cytovant Synovial sarcoma, MM, solid (CVT-TCR-01) tumors (NY-ESO-1) T
Slide 5: Clinical trials – key information
Clinical trials – key information MDG1011 – ongoing Product: Autologous TCR-T cells specific for HLA-A*02:01-restricted PRAME Trial: Phase I/II – dose-escalating, safety/feasibility Indications: Myeloid (AML, MDS) and lymphoid (MM) malignancies MDG1021 – starting H1 2020 Product: Donor TCR-T cells s
Slide 6: Advancing towards solid tumors – inducible TCR system (iM-TCR)
Advancing towards solid tumors – Medigene‘s inducible TCR system (iM-TCR) Tamoxifen iM-TCRs carry Tamoxifen Mutations that inhibit Well-known and well- natural TCRαβ pairing characterized drug Dimerizes mutated tails Mutated tails leading to TCRαβ pairing iM-TCR displayed on T cell surface only afte
Slide 7: Advancing towards solid tumors – Co-stimulatory switch receptor PD1-41BB
Advancing towards solid tumors – Co-stimulatory switch receptor PD1-41BB HLA TCR Inhibition T cell Inhibition Tumor Exhaustion cell Apoptosis PD-L1 PD-1 HLA TCR Effector functions T cell Activation Tumor Survival cell Longevity PD-L1 PD1-41BB Overcoming inhibitory signals in the tumor milieu through
Slide 8: Partnerships validate Medigene's technologies
Partnerships validate Medigene’s technologies TCRs bluebird bio ▪ 6 TCR discovery projects for defined antigen/HLA combinations ▪ Worldwide development and commercial rights and exclusive license for IP ▪ First TCR lead for MAGE-A4/HLA-A2 selected for clinical development starting in 2020 ▪ Potentia
Slide 9: Financial review and outlook – Financial guidance 2019 confirmed
Financial review and outlook – Financial guidance 2019 confirmed 9M 2019 GUIDANCE 2019 Total revenues €6.9 m €10-11 m R&D expenses €16.5 m €24-29 m EBITDA loss €18.6 m €23-28 m Liquid assets and time deposits as of 30 September 2019 amounted to €60.5 m Medigene has sufficient financial resources for
Slide 10: Expected development milestones
Expected development milestones 2019 2020 Clinical trials Clinical trials ✓ Treatment of patients in 1st dose cohort of Topline data on Phase I/II DC vaccine trial Phase I MDG1011 trial and expansion of (2-years-treatment) clinical trial sites MDG1011 Phase I dose escalation trial in ✓ Interim analy
Slide 11: Thank you! Questions & Answers
medigene Thank you! Questions & Answers
Slide 12: Medigene AG contact details
Medigene AG T +49 - 89 - 20 00 33 - 0 Lochhamer Straße 11 F +49 - 89 - 20 00 33 - 2920 82152 Planegg / Martinsried [email protected] Germany www.medigene.com Listed on Frankfurt Stock Exchange (MDG1, Prime Standard)